Quidel SafePlan
This article was originally published in The Gray Sheet
Executive Summary
FDA tells Quidel that it must submit a premarket approval application for its SafePlan fertility awareness test, which measures hormone concentrations in urine to determine when a woman is in the "post-ovulatory, non-fertile phase" of her menstrual cycle and therefore "biologically unable to become pregnant," the firm explains. Quidel submitted a 510(k) for the product in October 1993; however, after reviewing the application, FDA concluded that SafePlan's "unique diagnostic measurement technology is not sufficiently similar to the predicate device" referenced in the 510(k), Quidel says
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.